A Clinical Trial Adriamycin (NSC 123127) in Advanced Sarcomas

Abstract

Patients (22) with advanced sarcomas received adriamycin, 20-25 mg/m2 per day for 3 days every 3 wk. Two patients manifested objective response for a median of 5 mo. Eight patients had stable disease for a median of 3 mo. Nausea and vomiting occurred in 21 of 22 patients; leukopenia in 11 of 22 and thrombocytopenia in 4 of 22. There was no clinically significant cardiotoxicity. This study indicates that this regimen for adriamycin was relatively ineffective in the management of these inoperable or metastatic malignancies.